LA CE APRUEBA IMDYLLTRA® DE AMGEN PARA EL CÁNCER DE PULMÓN DE CÉLULAS PEQUEÑAS EN ESTADIO AVANZADO
FDA DecisionapprovedIMDYLLTRAPositive
AI Analysis
Summary
The FDA approved IMDYLLTRA from Amgen for advanced small cell lung cancer based on Phase 3 DeLLphi-304 data showing a 40% reduction in mortality risk compared to chemotherapy. This represents a new treatment option for patients with advanced disease who have progressed.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
FDA approval for advanced small cell lung cancer based on Phase 3 DeLLphi-304 trial demonstrating 40% reduction in mortality risk versus chemotherapy
Importance:9/10
Sentiment:
0.90
FDA approvaloncologysmall cell lung cancerPhase 3 datamortality benefit
Related Companies
Read the original article
Published by PR Newswire Biotech on June 3, 2026 1:27 PM